Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Gross Margin (2021 - 2025)

Historic Gross Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to 89.28%.

  • Rhythm Pharmaceuticals' Gross Margin rose 7900.0% to 89.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 89.4%, marking a year-over-year increase of 7900.0%. This contributed to the annual value of 89.73% for FY2024, which is 17400.0% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Gross Margin of 89.28% as of Q3 2025, which was up 7900.0% from 88.57% recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Gross Margin ranged from a high of 95.83% in Q2 2022 and a low of 50.0% during Q2 2021
  • In the last 5 years, Rhythm Pharmaceuticals' Gross Margin had a median value of 88.49% in 2024 and averaged 86.22%.
  • Per our database at Business Quant, Rhythm Pharmaceuticals' Gross Margin soared by 458300bps in 2022 and then plummeted by -74600bps in 2023.
  • Quarter analysis of 5 years shows Rhythm Pharmaceuticals' Gross Margin stood at 87.01% in 2021, then grew by 1bps to 88.3% in 2022, then dropped by -2bps to 86.66% in 2023, then rose by 5bps to 90.95% in 2024, then fell by -2bps to 89.28% in 2025.
  • Its Gross Margin stands at 89.28% for Q3 2025, versus 88.57% for Q2 2025 and 88.85% for Q1 2025.